Indication intelligence, analysis and sector perception

RegMedInvestors (RMi):Sage Therapeutics (SAGE) has unanimously rejected Biogen’s (BIIB) $469 M offer

January 27, 2025

Breaking: SAGE board has unanimously rejected Biogen’s (BIIB) $469 M offer, stating it "significantly undervalues" the company and does not serve shareholders' best interests. BIIB, which currently holds a 10.2% stake in Sage, proposed to acquire all outstanding Sage shares it does not already own for $7.22 per share. SAGE also announced it has initiated a process to explore strategic alternatives but has not set a timeline for the review. SAGE confirmed (2/10/25) that Biogen (BIIB) has submitted an unsolicited, nonbinding proposal to acquire all of the outstanding shares of SAGE not already owned by BIIB for $7.22 per share. SAGE is trading (Monday, 1/27/25) up +$0.39 or -5.42% at $7.49

RegMed Investors (RMi): Happy New Year – 2025

January 1, 2025

“Last year's words .... belong to last year's language.  And next year's words ... await another voice” — TS Eliot          

Merry Christmas and Happy Holiday to All

December 23, 2024

To RegMed Investor (RMi) readers, one and all …   It’s been quite the year, 2024; more bottoms than peaks, a blend of fortune and losses. To you ... Christmas and Holiday wishes go a long way in maintaining relationships that have created bonds that WILL only become stronger with time.  Whether you've been reading my insights from writings; I have been pretty damn right through the year! 2025 is just another road to be traveled … in safety!   So, as you navigate the holiday hustle, remember to take a moment for some well-deserved relaxation and maybe a cocktail or two. Wishing you all a holiday season and fewer reasons to check your email!